[{"address1": "National Innovation Centre", "address2": "Suite 212a 2 4 Cornwallis Street Eveleigh", "city": "Sydney", "state": "NSW", "zip": "2015", "country": "Australia", "phone": "61 2 9209 4037", "fax": "61 2 9209 4037", "website": "https://www.claritypharmaceuticals.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.", "fullTimeEmployees": 41, "maxAge": 86400, "priceHint": 4, "previousClose": 3.23, "open": 3.34, "dayLow": 3.23, "dayHigh": 3.34, "regularMarketPreviousClose": 3.23, "regularMarketOpen": 3.34, "regularMarketDayLow": 3.23, "regularMarketDayHigh": 3.34, "beta": 1.548, "volume": 6000, "regularMarketVolume": 6000, "averageVolume": 11498, "averageVolume10days": 14677, "averageDailyVolume10Day": 14677, "bid": 3.0, "ask": 3.32, "askSize": 40000, "marketCap": 1006616640, "fiftyTwoWeekLow": 0.4827, "fiftyTwoWeekHigh": 3.75, "priceToSalesTrailing12Months": 106.11398, "fiftyDayAverage": 2.680606, "twoHundredDayAverage": 1.6339033, "currency": "USD", "enterpriseValue": 773780480, "floatShares": 179164846, "sharesOutstanding": 311646016, "heldPercentInsiders": 0.29373, "heldPercentInstitutions": 0.06712, "impliedSharesOutstanding": 332436992, "bookValue": 0.202, "priceToBook": 15.990099, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -30562508, "trailingEps": -0.08, "enterpriseToRevenue": 81.569, "enterpriseToEbitda": -23.719, "52WeekChange": 5.4128857, "SandP52WeekChange": 0.26238096, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CLRPF", "underlyingSymbol": "CLRPF", "shortName": "CLARITY PHARMACEUTICALS LTD", "longName": "Clarity Pharmaceuticals Ltd", "firstTradeDateEpochUtc": 1677508200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e3adc917-5183-3806-b4b8-3bebee6c5494", "messageBoardId": "finmb_263530964", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.23, "recommendationKey": "none", "totalCash": 37982804, "totalCashPerShare": 0.145, "ebitda": -32623064, "quickRatio": 10.905, "currentRatio": 11.762, "totalRevenue": 9486183, "revenuePerShare": 0.036, "returnOnAssets": -0.27666, "returnOnEquity": -0.45330003, "freeCashflow": -28502352, "operatingCashflow": -37663704, "revenueGrowth": -0.055, "grossMargins": 1.0, "operatingMargins": -3.3585901, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]